arrow
A

Alice C. O'Farrell

rcsi university of medicine and health sciences
H指数:11
被引数:684

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evaluating the NFPp10a/NF5310 glioblastoma model as a faithful avatar for screening tumour microenvironment–targeted therapies

评估NFPp10a/NF5310胶质母细胞瘤模型作为忠实替身用于筛选肿瘤微环境靶向疗法

2026-09-040
OAAI
Bevacizumab for Metastatic Colorectal Cancer with Chromosomal Instability: Cost-Effectiveness Analysis for a Novel Precision Treatment Approach in Germany, Ireland and Spain

贝伐珠单抗用于染色体不稳定性转移性结直肠癌:德国、爱尔兰和西班牙一种新型精准治疗方法的成本效益分析

2026-02-040
PRE
Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers
2023-08-2410
OA
Comparative analysis of deeply phenotyped GBM cohorts of 'short-term' and 'long-term' survivors
2023-05-264
OAAI
Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy

新型胶质母细胞瘤肿瘤微环境亚型的鉴定,验证和生物学特征: 对精确免疫疗法的影响

2023-03-0138
OAAI
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts (vol 53, pg 86, 2021)

在患者来源的癌症异种移植物的植入和传代过程中保留拷贝数谱 (第53卷,第86页,2021页)

2021-02-194
OAAI
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

在患者来源的癌症异种移植物的植入和传代过程中保留拷贝数谱

2021-01-07125
OAAI
Absence of mouse-specific tumor evolution in patient-derived cancer xenografts
2020-08-150
PRE
Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 trial
2019-07-2410
OAAI